Cargando…

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease

OBJECTIVE: End-stage chronic liver disease is associated with accelerated ageing and increased frailty. Frailty measures have provided clinical utility in identifying patients at increased risk of poor health outcomes, including those awaiting liver transplantation. However, there is limited data on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naimimohasses, Sara, O'Gorman, Philip, McCormick, Emma, Ferguson, Damien, Monaghan, Ann, McGrath, Marie, Robinson, Mark W, Gormley, John, Norris, Suzanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083434/ https://www.ncbi.nlm.nih.gov/pubmed/35523460 http://dx.doi.org/10.1136/bmjgast-2021-000861

Ejemplares similares

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
por: Asfari, Mohammad Maysara, et al.
Publicado: (2020)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease
por: Mehta, Rohini, et al.
Publicado: (2016)

Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD)
por: O'Gorman, Philip, et al.
Publicado: (2021)

Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia
por: Rahman, M Masudur, et al.
Publicado: (2020)

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
por: Wood, Kayleigh L, et al.
Publicado: (2015)

Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review
por: Kenneally, Susan, et al.
Publicado: (2017)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
por: Tincopa, Monica A, et al.
Publicado: (2021)

Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya
por: Mburu, Anne Njeri, et al.
Publicado: (2023)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
por: Afonso, Marta B, et al.
Publicado: (2021)

Low yield of head CT in cirrhotic patients presenting with hepatic encephalopathy
por: Hanna, Angy, et al.
Publicado: (2021)

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease
por: O'Brien, Alastair
Publicado: (2022)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway
por: Wu, Heng, et al.
Publicado: (2016)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
por: Koh, Eun Hee, et al.
Publicado: (2021)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
por: Haigh, Laura, et al.
Publicado: (2021)

Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction
por: Choi, Jong Wook, et al.
Publicado: (2019)

Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey
por: Takahashi, Atsushi, et al.
Publicado: (2020)

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
por: Tang, Xiaoping, et al.
Publicado: (2022)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Relationship between Streptococcus mutans expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: a pilot study
por: Tonomura, Shuichi, et al.
Publicado: (2019)

Adiponectin–leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance
por: Lu, Chia-Wen, et al.
Publicado: (2023)

Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression
por: Loyer, Xavier, et al.
Publicado: (2016)

Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging
por: Blake, Laurence, et al.
Publicado: (2016)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway
por: Li, Meng, et al.
Publicado: (2018)

Development and relative validation of a short food frequency questionnaire for assessing dietary intakes of non-alcoholic fatty liver disease patients
por: Bredin, Carla, et al.
Publicado: (2019)

Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study
por: Coelho, Juliana Moraes, et al.
Publicado: (2020)

Association of physical activity and fine motor performance in individuals with type 2 diabetes mellitus and/or non-alcoholic fatty liver disease
por: Weinstein, Ali A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tge2rnjbs3kju8g30vndv64rgj